Intranasal Drug Delivery Applications Market

Intranasal Antiviral Drugs Emerge as Solution for Prevention of COVID-19 Transmission

The rapid spread of coronavirus (COVID-19) has created relevance for intranasal drug delivery for current and future clinical trials. Companies in the intranasal drug delivery applications market are innovating in vaccines in the form of nasal drops for the prevention and treatment of coronavirus and other potential viral diseases. However, companies need to consider the possibility of adverse reactions in patients.

Intranasal delivery of antiviral drugs or agents is emerging as an additional option for preventing the transmission of COVID-19. Companies in the intranasal drug delivery applications market should collaborate with specialists in infectious diseases, otolaryngology, and virology to advance in intranasal administration of drugs and agents. They should conduct video conferences to discuss the outcomes of their research activities. As such, manufacturers need to focus on minimizing potential intranasal adverse reactions such as mucosal or skin irritation and headaches.

Nano-technological Approaches Help Overcome Blood-Brain Barrier

The complex structure of the nasal cavity causes degradation of enzymes present in the nasal cavity. Blood-brain barrier (BBB) tend to restrict the transportation of nasal therapeutic agents to the brain. Such issues are causing roadblock in the expansion of the intranasal drug delivery applications market. Hence, manufacturers are adopting nano-technological approaches, such as nano-emulsions, solid lipid nanoparticles, and liposomes, among others, to overcome the issues associated with BBB.

Companies in the intranasal drug delivery applications market are increasing their research in drugs that directly target the brain by olfactory and the trigeminal nerve pathway to bypass the BBB. Pathological conditions such as common cold and rhinitis result in major disputes for nasal drug delivery. Hence, manufacturers are relying on nano-technological approaches such as polymeric nanoparticles and polymeric micelles to overcome BBB.

Flexible Drug-Device Combination Products Facilitate Direct Nose-to-Brain Delivery

Manufacturers in the intranasal drug delivery applications market are providing non-invasive direct nose-to-brain delivery. For instance, SipNose— a provider of devices for a wide variety of neurological disorders, is innovating in nose-to-brain medical applications to advance in treatments for neurological disorders. Companies in the in the intranasal drug delivery applications market are taking cues from such innovations to create flexible platforms that are suitable for home and clinical use.

There is a growing demand for intranasal drug delivery solutions catering to emergency and daily administration of pediatric, geriatric, and adult patients. FDA (Food and Drug Administration)–approved nasal devices are helping manufacturers gain market recognition. Collaborations with worldwide pharmaceutical and biopharmaceutical companies are helping manufacturers to innovate in drug-device combination products.

Innovative Nasal Devices Assist in Localization of Aerosolized Drugs

Accurate dose delivery via the nasal cavity is an important aspect of intranasal drug application. Innovative nasal devices are facilitating efficiency in the delivery of therapeutic agents. Hence, manufacturers in the intranasal drug delivery applications market are increasing their production capabilities in devices that enable reproducible and consistent dosing. They are developing devices that are compatible with a wide range of formulations involving dry powders, liquids, small and large molecule biologics, and cells.

Reusable and one-time use nasal devices are creating value-grab opportunities for manufacturers in the intranasal drug delivery applications market. High compliance and non-invasive nasal devices are facilitating optimal mixing of powders and liquids for drug delivery. Better localization of aerosolized drugs with the help of innovative nasal devices is being highly preferred by patients with neural diseases.

R&D in Nasal Pathology Helps Compare Administration Procedures of Different Nasal Drugs

Various drug delivery mechanisms result in different pharmacokinetic profiles for multiple drugs. These delivery differences are crucial for understanding the administration of topically acting medications. Companies in the intranasal drug delivery applications market are studying these differences in drug delivery to assess the safety and efficacy of medications inhaled into the lower respiratory tract. A comparative assessment of drugs administered to the upper respiratory tract can be evaluated to assess differences in nasal drug deposition.

In order to achieve high and deep intranasal drug deposition, manufacturers in the intranasal drug delivery applications market are gaining a strong research base in nasal pathology. Anatomy of the nasal labyrinth is complex with multiple obstructing surfaces and meatuses. Hence, companies are adhering to regulatory guidance to conduct in vitro tests such as droplet or particle distribution, emitted dose, and spray pattern to compare the administration of nasal drugs.